Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Peter, Jonny ^a,b,g   Theron, Grant ^a   Chanda, Duncan ^a,c   Clowes, Petra ^d,e   Rachow, Andrea ^e,f   Lesosky, Maia ^g   Hoelscher, Michael ^e,f   Mwaba, Peter ^c   Pym, Alex ^h,i   Dheda, Keertan ^a,g   Pretorius, M ^j   Pascoe, M ^j   Soetwater, B ^j   Wyngard, M ^j   Pool, L ^j   Viny, C ^j   Kasonde, M ^j   Manjeta, L ^j   Mthiyane, T ^j   Ntshuba, N ^j   Gumede, S ^j   Mvuyane, T ^j   Mbambo, P ^j   Mangu, C ^j   Kayombo, F ^j   Temihanga, A ^j   Kimaro, M ^j   Mnyanyi, B ^j   Mgogo, I ^j   Ambukege, B ^j   Sanga, T ^k   Meldau, R ^j   Woodbourne, V ^j   Hope, P ^j   Mzyece, J ^j   Madaar, F ^j   Mbilinyi, H ^j   Rojas Ponce, G ^j   Mapamba, D ^j   Lueer, C ^j   Bauer, A ^j   Njovu, L ^k   Cogill, D ^j   Louw, V ^j   Kapotwe, V ^j   Connolly, C ^j   Kowuor, D ^j   Chiwerengo, N ^j   Edwards, S ^k   more..

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY TEACHING HOSPITAL   (Zambia)

^d NATIONAL INSTITUTE OF MEDICAL RESEARCH   (Tanzania)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f German Centre for Infection Research (DZIF)   (Germany)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

ⁱ AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^j NONE

^k Chunya District Council Health Department   (Tanzania)

more..

Author keywords

Diagnosis; LAM lateral flow assay; Patient important impact outcomes; Tuberculosis

Indexed keywords

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEATH; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE MICROSCOPY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INTERMETHOD COMPARISON; LATERAL FLOW ASSAY; LIQUID CULTURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENT; POINT OF CARE TESTING; PREDICTIVE VALUE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; TANZANIA; THORAX RADIOGRAPHY; TUBERCULOSIS RAPID TEST; URINALYSIS; ZAMBIA; BIOASSAY; COMPLICATION; DIAGNOSTIC TEST; HOSPITAL INFORMATION SYSTEM; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; MIXED INFECTION; OUTPATIENT DEPARTMENT; PROSPECTIVE STUDY; SPUTUM; TUBERCULOSIS; TUBERCULOSIS, PULMONARY; URINE; YOUNG ADULT;

LIPOARABINOMANNAN; LIPOPOLYSACCHARIDE;

ADULT; AGED; AMBULATORY CARE FACILITIES; BIOLOGICAL ASSAY; CD4 LYMPHOCYTE COUNT; COINFECTION; CROSS-SECTIONAL STUDIES; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; OUTPATIENTS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM; TANZANIA; TUBERCULOSIS; TUBERCULOSIS, PULMONARY; URINALYSIS; YOUNG ADULT; ZAMBIA;

EID: 84936154757     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0967-z     Document Type: Article

References (42)

1. WHO. WHO Report 2013: Global tuberculosis control. Geneva: World Heath Organisation; 2013. ISBN 978 92 4 156438 0.
2. Dowdy DW, Chaisson RE, Moulton LH, Dorman SE. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS. 2006;20(5):751-62.
3. Lin HH, Dowdy D, Dye C, Murray M, Cohen T. The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ. 2012;90(10):739-47A. doi: 10.2471/blt.11.101436. Epub 2012/10/31
4. Yoon C, Cattamanchi A, Davis JL, Worodria W, den Boon S, Kalema N, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS One. 2012;7(11), e48599. doi: 10.1371/journal.pone.0048599.
5. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383(9915):424-35. doi: 10.1016/S0140-6736(13)62073-5.
6. Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg. South Africa PLoS One. 2013;8(6), e65421. doi: 10.1371/journal.pone.0065421.
7. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495-505. Epub 2011/04/22. doi: 10.1016/S0140-6736(11)60438-8.
8. Theron G, Peter J, Dheda K. Xpert MTB/RIF test for tuberculosis. Lancet. 2011;378(9790):481. doi: 10.1016/S0140-6736(11)61242-7. author reply 2-3. Epub 2011/08/09.
9. Peter JG, Theron G, Singh N, Singh A, Dheda K. Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings. Eur Respir J. 2014;43(1):185-94. doi: 10.1183/09031936.00198012.
10. Alere. Alere Determine TB LAM Ag 2014 [cited 2014 7th April 2014]. Available from: http://www.alere.com/ww/en/product-details/determine-tb-lam.html.
11. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012;12(3):201-9. doi: 10.1016/S1473-3099(11)70251-1.
12. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed hiv-infected adults: a prospective, clinic-based study. BMC Infect Dis. 2014;14(1):110. doi: 10.1186/1471-2334-14-110. Epub 2014/02/28.
13. Balcha TT, Winqvist N, Sturegard E, Skogmar S, Reepalu A, Jemal ZH, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Tropical medicine & international health: TM & IH. 2014. doi: 10.1111/tmi.12308.
14. Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, Armstrong DT, et al. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr. 2014. Epub 2014/03/29. doi: 10.1097/qai.0000000000000151.
15. Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, Boehme CC, et al. Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies. BMC Infect Dis. 2013;13:407. doi: 10.1186/1471-2334-13-407.
16. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012;40(5):1211-20. doi: 10.1183/09031936.00201711. Epub 2012/03/01.
17. Shah M, Ssengooba W, Armstrong D, Nakiyingi L, Holshouser M, Ellner JJ, et al. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals with suspected tuberculosis in Uganda. AIDS. 2014. Epub 2014/03/19. doi: 10.1097/qad.0000000000000264.
18. Drain PK, Grobler A, Gounder L, Sahid F, Wilson D, Bassett IV, et al. Rapid urine lipoarabinomannan testing after two months of tuberculosis treatment independently predicts mortality in a resource-limited setting. 44th Union World Conference on Lung Health; December, 2013. Paris: The International Journal of Tuberculosis and Lung Disease; 2013. p. S264.
19. Drain PK, Grobler A, Gounder L, Sahid F, Wilson D, Bassett IV, et al. Point-of-care urine lipoarabinomannan for diagnosis and treatment response of pulmonary tuberculosis in sputum smear-negative suspects. Int J Tuberc Lung Dis. 2013;17(12):S277.
20. Aderaye G. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings: World Health Organization; 2007.
21. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007;369:2042-9.
22. Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, Andersen PL, et al. TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis. 2008;40(2):111-20. doi: 10.1080/00365540701558698.
23. Dean AG SK, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. http://www.OpenEpi.com , updated 2010/19/09, accessed 2010/11/30.
24. Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2005. ISBN 3-900051-07-0.
25. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138(1):W1-12. Epub 2003/01/07. doi: 200301070-00012-W1.
26. Peter JG, Theron G, Dheda K. Urine antigen test for diagnosis of HIV-associated tuberculosis. Lancet Infect Dis. 2012;12(11):825. doi: 10.1016/s1473-3099(12)70220-7. author reply 6-7. Epub 2012/10/27.
27. Shah M, Martinson NA, Chaisson RE, Martin DJ, Variava E, Dorman SE. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol. 2010;48(8):2972-4. doi: 10.1128/jcm.00363-10. Epub 2010/06/11.
28. Talbot E, Munseri P, Teixeira P, Matee M, Bakari M, Lahey T, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One. 2012;7(3):e32876. doi: 10.1371/journal.pone.0032876. Epub 2012/03/14.
29. Gounder CR, Kufa T, Wada NI, Mngomezulu V, Charalambous S, Hanifa Y, et al. Diagnostic Accuracy of a Urine Lipoarabinomannan Enzyme-Linked Immunosorbent Assay for Screening Ambulatory HIV-Infected Persons for Tuberculosis. J Acquir Immune Defic Syndr. 2011;58(2):219-23. doi: 10.1097/QAI.0b013e31822b75d4. Epub 2011/07/19.
30. Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One. 2010;5(3), e9848. doi: 10.1371/journal.pone.0009848. Epub 2010/03/31.
31. Mutetwa R, Boehme C, Dimairo M, Bandason T, Munyati SS, Mangwanya D, et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis. 2009;13(10):1253-9. Epub 2009/10/02.
32. Daley P, Michael JS, Hmar P, Latha A, Chordia P, Mathai D, et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis. 2009;13(8):989-95. Epub 2009/09/03.
33. Reither K, Saathoff E, Jung J, Minja LT, Kroidl I, Saad E, et al. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infect Dis. 2009;9:141.
34. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23(14):1875-80. Epub 2010/01/29.
35. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Value of urine lipoarabinomannan grade and second test for optimizing clinic-based screening for HIV-associated pulmonary tuberculosis. J Acquir Immune Defic Syndr. 2015;68(3):274-80. doi: 10.1097/QAI.0000000000000436.
36. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, Murray S, et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med. 2011;184(1):132-40. doi: 10.1164/rccm.201101-0056OC.
37. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. The Cochrane Database Syst Rev. 2014;1:CD009593. doi: 10.1002/14651858.CD009593.pub3.
38. Treatment Action Group MSF. Paris meeting on TB point-of-care test specifications. 2009.
39. Kroidl I, Clowes P, Mwakyelu J, Maboko L, Kiangi A, Rachow A, et al. Reasons for false-positive lipoarabinomannan ELISA results in a Tanzanian population. Scand J Infect Dis. 2014;46(2):144-8. doi: 10.3109/00365548.2013.853133. Epub 2013/11/28.
40. Peter JG, Theron G, Dheda K. Can point-of-care urine LAM strip testing for tuberculosis add value to clinical decision making in hospitalised HIV-infected persons? PLoS One. 2013;8(2):e54875. doi: 10.1371/journal.pone.0054875. Epub 2013/02/08.
41. Peter JG, Theron G, Muchinga TE, Govender U, Dheda K. The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce. PLoS One. 2012;7(7):e39966. doi: 10.1371/journal.pone.0039966.
42. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J. 2011;38(6):1398-405. doi: 10.1183/09031936.00025711. Epub 2011/06/28.